Prescriptions for insulin glargine-yfgn (Semglee) rapidly increased when its status switched from a standard biosimilar to ...

Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...

Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...

ISLAMABAD, Apr 23 (China Economic Net) - The insulin glargine cartridge by Gan & Lee Pharmaceuticals just obtained the first biosimilar approval from the Drug Regulatory Authority of Pakistan (DRAP), ...

Inclusion of basal insulin glargine in multiple daily injection (MDI) regimens decreases glycemic variability in adolescents with type 1 diabetes mellitus (T1DM), according to US researchers.

The marketing authorisation for the Alliance's insulin glargine product is based upon a comprehensive clinical data programme, which showed it has similar efficacy and safety compared to Lantus in ...

Glargine U300 use was common, especially with increased CKD stages and baseline HbA1c levels among patients with type 2 diabetes.

One group received two oral drugs (metformin plus the sulfonylurea glimepiride [Amaryl]) plus morning doses of glargine insulin (Lantus); the other group received twice-daily premixed insulin (70% ...

Hyperglycemia is a marker for poor clinical outcome and mortality in hospitalized patients. In the critical care setting, insulin administered intravenously or subcutaneously is effective.